TRYNGOLZA Trademark

Trademark Overview

On Monday, October 16, 2023, a trademark application was filed for TRYNGOLZA with the United States Patent and Trademark Office. The USPTO has given the TRYNGOLZA trademark a serial number of 98225238. The federal status of this trademark filing is REGISTERED as of Tuesday, May 27, 2025. This trademark is owned by Ionis Pharmaceuticals, Inc.. The TRYNGOLZA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders
tryngolza

General Information

Serial Number98225238
Word MarkTRYNGOLZA
Filing DateMonday, October 16, 2023
Status700 - REGISTERED
Status DateTuesday, May 27, 2025
Registration Number7812639
Registration DateTuesday, May 27, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 16, 2024

Trademark Statements

Goods and ServicesPharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 23, 2023
Primary Code005
First Use Anywhere DateMonday, December 30, 2024
First Use In Commerce DateMonday, December 30, 2024

Trademark Owner History

Party NameIonis Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010
Party NameIonis Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010
Party NameIonis Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010

Trademark Events

Event DateEvent Description
Thursday, October 19, 2023NEW APPLICATION ENTERED
Sunday, June 2, 2024ASSIGNED TO EXAMINER
Wednesday, June 26, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 12, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 10, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 25, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, September 25, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 25, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 5, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, September 25, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, September 25, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, September 25, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 5, 2025USE AMENDMENT FILED
Wednesday, February 5, 2025SOU EXTENSION 1 FILED
Wednesday, February 5, 2025TEAS STATEMENT OF USE RECEIVED
Friday, April 25, 2025STATEMENT OF USE PROCESSING COMPLETE
Friday, April 25, 2025SOU EXTENSION 1 GRANTED
Saturday, May 3, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Saturday, April 26, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, May 3, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 27, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 27, 2025REGISTERED-PRINCIPAL REGISTER

Related Keywords

tryngolza pharmaceuticals diseases disorders treatment inflammatory neurological cardiovascular genetic metabolic